Cryoport, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated April 6, 2015 (filed May 13, 2015), details a private placement of securities by Cryoport, Inc. The company entered into definitive agreements between April 6, 2015, and May 12, 2015, to raise capital from institutional and accredited investors.
Key Financial Metrics and Transaction Details
- Gross Proceeds (April 6 - May 12): $3,742,044
- Net Proceeds (Estimated): Approximately $3,258,178 after cash offering expenses
- Securities Issued: 311,837 Units
- Unit Composition: One share of Class B Preferred Stock and one warrant to purchase eight (8) shares of Common Stock.
- Warrant Terms: Exercise price of $0.50 per share; immediately exercisable; expiration date of May 31, 2020.
- Unit Price: $12.00 per Unit
- Placement Agent Fees: 10% commission plus a 3% non-accountable finance fee on gross proceeds, plus up to $5,000 in legal expense reimbursement.
- Placement Agent Warrants: Emergent Financial Group, Inc. received warrants to purchase three shares of Common Stock at $0.50 per share for each Unit issued.
Material Changes and Cumulative Totals
Through May 12, 2015, the company reported aggregate gross cash proceeds of $5.7 million (approximately $5.0 million net) from the broader offering. This cumulative total includes the issuance of 473,546 shares of Class B Preferred Stock and warrants exercisable for 3,788,368 shares of Common Stock at $0.50 per share.
Management Commentary, Risks, and Unusual Items
- Use of Proceeds: Net proceeds are intended for working capital purposes.
- Related Party Transaction: One investor was the spouse of Mr. Richard Berman, a director of the Registrant, who invested $20,000 for 1,667 Units.
- Regulatory Exemption: The sale was conducted under Regulation D and Section 4(2) of the Securities Act of 1933, exempt from public offering registration.
- Reference Documents: Full terms are detailed in Exhibits 10.1 and 4.1 of a prior Form 8-K filed on February 20, 2015.
Investor Verification Checklist
- Verify the dilution impact of 3,788,368 potential common shares from warrants exercisable at $0.50.
- Confirm the exact net cash received after all offering expenses and agent fees.
- Review the full text of the Subscription Agreements (Exhibit 10.1) and Warrant Agreements (Exhibit 4.1) referenced in the filing.
- Assess the liquidity implications of the Class B Preferred Stock terms not fully detailed in this summary.